Elpamotide Uses, Dosage, Side Effects and more
Elpamotide is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)).
| Attribute | Details |
|---|---|
| Trade Name | Elpamotide |
| Generic | VEGFR2-169 |
| VEGFR2-169 Other Names | Elpamotide, Vegfr2-169 peptide vaccine |
| Type | |
| Formula | C47H76N16O13 |
| Weight | Average: 1073.224 Monoisotopic: 1072.577776571 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
